Clinigen appoints Sam Herbert as Chief Operating Officer
Clinigen Group plc (‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Sam Herbert as Chief Operating Officer. His appointment is effective immediately and he will be based in the UK.
Sam is an experienced international healthcare pharmaceutical executive with a background in driving growth and change in global supply and distribution businesses. He brings a track record of leading businesses through commercial and service expansion which will support Clinigen’s growth plans as it continues to realise its vision of becoming the global leader in access to medicines.
Before joining Clinigen, he spent seven years at World Courier, a leading provider of specialty logistics and distribution services to the pharmaceutical, biotech and healthcare community. He joined as Vice President, Strategy, rising to become Chief Operating Officer and finally, President. His role developed from leading on the implementation of a transformation strategy following World Couriers’ acquisition by AmerisourceBergen in 2012 to ultimately driving the overall company’s performance as President, responsible for >3,000 people across 56 countries. Prior to World Courier, Sam worked for Oliver Wyman, a leading international management consulting firm and built their Health & Life Sciences practice in Europe.
Sam has an AB in Economics (cum laude) from Harvard College and is a Non-Executive Director of 7Bridges, an innovative AI-driven logistics platform company.
Shaun Chilton, Group Chief Executive Officer, Clinigen, said:
“We have been building out Clinigen’s global platform in order to fully realise our vision of being the Trusted Global Leader in Access to Medicines. Now, more than ever, Clinigen has an important role to play in getting essential medicines across the world to the patients that need them. In adding the Chief Operating Officer role and with it, someone of Sam’s calibre and experience into the management team, this gives us more bandwidth and will significantly help us focus on executing our growth strategy and the significant number of opportunities the platform is creating.”
Sam Herbert, new Chief Operating Officer, said:
“I am excited about joining Clinigen at such an important time in its development as a company. It is clear that the challenge to enable access to increasingly complex medicines across the world has increased exponentially. I am looking forward to joining the team at Clinigen and using my experience to help the Group meet the needs of its pharma clients and HCP customers alike, in order to benefit patients.”
Clinigen Group plc
Shaun Chilton, Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Tel: +44 (0) 1283 495 010
Numis Securities Limited - Nominated Adviser & Joint Broker
James Black / Garry Levin / Freddie Barnfield
Tel: +44 (0) 20 7260 1000
RBC Capital Markets - Joint Broker
Marcus Jackson / Elliot Thomas
Tel: +44 (0)20 7653 4000
Melanie Toyne Sewell / Phillip Marriage
Tel: +44 (0)20 7457 2020
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com